Stevanato Group S.p.A. (STVN) CFO Marco Sells 7,997 Shares
Chief Financial Officer Marco Dal Lago recently parted with shares of Stevanato Group S.p.A. as executive transactions continue at the medical device maker.
Reviewed by automated data checks against the source filing. How we make and check alerts
Dal Lago Marco, Chief Financial Officer at Stevanato Group S.p.A. ($STVN), sold 7,997 shares on June 12, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $STVN is down 0.8% after 1 week, up 15.8% after 1 month and up 10.7% to date (from the $17.08 close on Jun 12, 2026).
STVN
Stevanato Group S.p.A.
Key Points
- Stevanato Group S.p.A. CFO Marco Dal Lago sold 7,997 shares of the company on June 12, 2026.
- The stock traded near $18.39, sitting between its 52-week low of $12.89 and high of $27.99.
- Recent insider activity includes multiple open-market acquisitions by board members and executives in June.
Get $STVN trade alerts by text
We text you when insiders, Congress or big funds trade $STVN. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Stevanato Group S.p.A. alert may contain errors. Disclosures
Stevanato Group CFO Sells Shares
Stevanato Group S.p.A. (NYSE: STVN) chief financial officer Marco Dal Lago sold 7,997 shares on June 12, 2026. The transaction follows a busy stretch of leadership trades at the Italian medical technology and drug containment firm. Insider transactions are common among corporate executives and do not inherently signal a bearish or bullish outlook for the company.
Stock Price Trades Near Moving Averages
The company's shares changed hands at $18.39 recently, hovering near its 200-day moving average of $18.19. The stock has traded in a 52-week range between $12.89 and $27.99. Stevanato Group carries a market capitalization of roughly $5.26 billion and a forward P/E ratio of 23.18.
Recent Insider Activity Across Leadership
The sale by Dal Lago adds to a flurry of recent insider moves recorded at the company during June 2026. On June 9, Chief Business Strategy Officer Mauro Stocchi completed transactions involving 6,586 shares. Later in the month on June 12, board members and affiliates including Sue-Jean Lin, Karen Flynn, Elisabetta Magistretti, and Madhavan Balachandran each acquired 4,975 shares.
Analysts Set New Price Targets
Wall Street firms maintain coverage on the medical equipment supplier, with UBS recently updating its view. On September 9, 2026, UBS maintained its Neutral rating on the stock while adjusting its price target to $23.00 from $28.00. The broader analyst consensus sits at a buy recommendation with a mean price target of $24.47 based on 13 analyst opinions.
Inside Stevanato Group's Operations
Stevanato Group S.p.A. designs and manufactures containment solutions, drug delivery systems, and diagnostic equipment for the biopharmaceutical and healthcare sectors worldwide. Founded in 1949 and headquartered in Piombino Dese, Italy, the company supplies pre-fillable syringes, vials, and automated inspection machinery to life sciences firms globally.
What to Watch Next for STVN
Investors will look toward the company's next earnings report, scheduled for November 5, 2026, for updated financial metrics and revenue figures. Future Form 4 filings with the SEC will also provide ongoing transparency regarding executive and director share ownership.
Related Filing Alerts
Source: Dal Lago Marco's Form 4 filing on $STVN (Jun 12, 2026). Find the original filing: STVN Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts